# 1 Evaluation of spike protein antigens for SARS-CoV-2

# <sup>2</sup> serology

| 3  | Suraj Jagtap <sup>a#</sup> , Ratnasri K <sup>b#</sup> , Priyanka Valloly <sup>a#</sup> , Rakhi Sharma <sup>a</sup> , Satyaghosh Maurya <sup>a</sup> , Anushree |
|----|--|
| 4  | Gaigore <sup>a</sup> , Chitra Ardhya <sup>c</sup> , Dayananda S. Biligi <sup>c</sup> , Bapu Koundinya Desiraju <sup>d</sup> , Uma Chandra Mouli                |
| 5  | Natchu <sup>e</sup> , Deepak Kumar Saini <sup>b,f</sup> , Rahul Roy <sup>a,b,*</sup>   |
| 6  |  |
| 7  | <sup>a</sup> Department of Chemical Engineering, Indian Institute of Science, Bangalore, 560012 India  |
| 8  | <sup>b</sup> Centre for BioSystems Science and Engineering, Indian Institute of Science, Bangalore, 560012   |
| 9  | India  |
| 10 | <sup>c</sup> Department of Pathology, Bangalore Medical College and Research Institute, Bangalore,   |
| 11 | 560002 India   |
| 12 | <sup>d</sup> Translational Health Science and Technology Institute, NCR Biotech Science Cluster,   |
| 13 | Faridabad, 121001 India  |
| 14 | <sup>e</sup> Division of Infectious Diseases, St. John's Research Institute, Bangalore, 560034 India   |
| 15 | <sup>f</sup> Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science,  |
| 16 | Bangalore, 560012 India  |
| 17 |  |
| 18 | # Contributed equally to this work.  |
| 19 |  |
| 20 | * Corresponding author: Rahul Roy (rahulroy@iisc.ac.in)  |
| 21 |  |
| 22 |  |
| 23 |  |

# 24 Highlights

| 25 | • | Spike trimer displays the highest antibody titer in SARS-CoV-2 infections among spike   |
|----|---|---|
| 26 |   | protein antigens.   |
| 27 | • | Spike trimer IgG ELISA displays a sensitivity of 50% within six days and 86.2% after 14 |
| 28 |   | days from onset of symptoms.  |
| 29 | • | IgA and IgG responses to spike trimer antigen were comparable and concomitant in time   |
| 30 |   | after infection.  |
| 31 | • | 16% (IgG) and 15% (IgA) of COVID-19 RT-PCR positive patients did not seroconvert even   |
| 32 |   | after 21 days from onset of symptoms.   |
|    |   |   |

## 34 Abstract

35 Keywords: SARS-CoV-2, serology, Spike trimer ELISA

36

Background: Spike protein domains are being used in various serology-based assays to detect
 prior exposure to SARS-CoV-2 virus. However, there has been limited comparison of human
 antibody titers against various spike protein antigens among COVID-19 infected patients.

Methods: We compared four spike proteins (RBD, S1, S2 and a stabilized spike trimer (ST)) representing commonly used antigens for their reactivity to human IgG antibodies using indirect ELISA in serum from COVID-19 patients and pre-2020 samples. ST ELISA was also compared against the EUROIMMUN IgG ELISA test. Further, we estimated time appropriate IgG and IgA seropositivity rates in COVID-19 patients using a panel of sera samples collected longitudinally from the day ofonset of symptoms (DOS).

46 **Results:** Among the four spike antigens tested, the ST demonstrated the highest sensitivity 47 (86.2%; 95% CI: 77.8-91.7%), while all four antigens showed high specificity to COVID-19 sera 48 (94.7-96.8%). 13.8% (13/94) of the samples did not show seroconversion in any of the four 49 antigen-based assays. In a double-blinded head-to-head comparison, ST based IgG ELISA 50 displayed a better sensitivity (87.5%, 95%CI: 76.4-93.8%) than the EUROIMMUN IgG ELISA 51 (67.9%, 95% CI: 54.8-78.6%). Further, in ST-based assays, we found 48% and 50% 52 seroconversion in the first six days (from DOS) for IgG and IgA antibodies, respectively, which 53 increased to 84% (IgG) and 85% (IgA) for samples collected  $\geq$ 22 days DOS.

54 Conclusions: Comparison of spike antigens demonstrates that spike trimer protein is a superior
 55 option as an ELISA antigen for COVID-19 serology.

56

#### 57 Introduction

58 COVID-19 pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-59 CoV-2) has already crossed 97 million detected cases and over 2 million deaths worldwide till 60 date [1]. As the pandemic continues, we need accurate and sensitive tests to assess the 61 prevalence, disease burden and the level of population immunity against the virus. With the 62 introduction of multiple vaccines and several ongoing vaccine trials, identifying prior exposure or 63 immunogenicity of the vaccine in individuals becomes critical to the development of vaccination 64 and public health strategies.

65 Nucleic acid-based tests that detect viral RNA are widely used to diagnose active infection in 66 SARS-CoV-2 infected individuals [2,3]. In contrast, immunological tests like serological assays 67 detect the level of human antibody response to the infection in symptomatic as well as the large 68 fraction of asymptomatic infections [4-7]. Immuno-assays detect antigen-specific IgA, IgM and 69 IgG immunoglobulins (antibodies) from body fluids like serum or plasma. Viral antigen-specific 70 antibodies can be detected in SARS-CoV-2 exposed individuals within 5-12 days post-onset of 71 symptoms (POS) for IgM and IgA antibodies and 14 days for IgG antibodies [8,9]. IgG antibodies 72 are long-lived, detectable for at least 8 months, making them promising recent and long term 73 markers of exposure to SARS-CoV-2 [10].

74 Serological assays with nucleocapsid or spike protein of SARS-CoV-2 as capturing antigen have 75 been widely developed and reported, as these antigens are highly immunogenic [11,12]. 76 Nucleocapsid protein bound to the viral RNA is significantly conserved among the coronaviruses, 77 contributing to false positives in immunoassays [13,14]. The spike (S) protein decorates the 78 exterior of SARS-CoV-2 virus and helps in host cell entry [15-17]. Anti-spike antibodies also 79 demonstrate high virus neutralization efficacy [18,19]. The spike glycoprotein is a clove-shaped 80 trimeric protein with each unit consisting of the S1 head and the S2 stalk. The Receptor Binding Domain (RBD) of the S1 head is responsible for binding to the ACE2 receptor on the cellular 81 82 membrane, initiating cell entry [16,20]. Due to the large size (153 KDa) of S protein and challenges

with achieving proper protein folding, it is difficult to express in bacteria and provides poor yields
using traditional mammalian expression systems. Capture antigens used for serological assays
should be easy to express and purify, with high yield and stability. Recently, the prefusion state
of SARS-CoV-2 spike trimer (ST) protein was stabilized by the addition of 6 prolines that improved
thermal stability and expression yield in mammalian cell suspension culture, making it a promising
antigen for SARS-CoV-2 antibody assays [21].

In this study, we evaluated the ST protein as a potential capture antigen for ELISA and compared
it with different subunits of S protein, namely, S1, S2 and RBD to assess IgG antibody titers in
SARS-CoV-2 positive and pre-pandemic sera. We also used ST protein to elucidate IgG and IgA
antibody response dynamics with time-stratified samples (≤6, 7-14, 15-21 and ≥22 days POS).
Further, we benchmarked the ST protein ELISA against an FDA approved (EUROIMMUN)
serology ELISA kit.

95

#### 96 Materials and methods

#### 97 Sample collection

98 For COVID-19 samples, 1-2 ml of blood was drawn from patients who had tested positive for 99 SARS-CoV-2 by RT-PCR test. One set of serum samples (n=69) of COVID-19 patients were 100 obtained from individuals hospitalized at Bangalore Medical College and Research Institute 101 (BMCRI) between April-May 2020. All these samples were collected ≥15 days post-onset of 102 symptoms or RT-PCR positivity (POS/RT). A separate set of serum samples (n=100; collected 103 between March-August 2020) were obtained from COVID-19 biorepository of Translational Health 104 Science and Technology Institute, Delhi (THSTI) that were time stratified along the course of 105 COVID-19 infection (25 samples each from day 0-6, 7-14, 15-21 and ≥22 days POS). For COVID-106 19 negative controls, serum samples collected during 2018-19 from healthy donors (n=33) and 107 dengue patients (n=61, Panbio dengue IgG/IgM capture ELISA kits, 01PE10/01PE20) and stored 108 in -80°C were used. We also tested the control samples for Influenza A/B antibodies (Immunolab

Influenza A/B IgG ELISA, ILE-IFA01/ILE-IFB01). Informed consent from patients was received as
 per study protocols approved by the Institute Ethics Committees of the institutes where samples
 were collected and assays were performed.

112

113 Protein expression and purification

114 The plasmids for RBD (pCAGGS vector containing the human codon-optimized RBD (amino acids 115 319-541) SARS-CoV-2, Wuhan-Hu-1 spike glycoprotein, GenBank: MN908947; a gift from Florian 116 Krammer, Mount Sinai, New York) and the ST protein (HexaPro; a gift from Jason McLellan, 117 University of Texas, Austin) were purified from DH5a strain of E. coli. The plasmids were 118 transfected into Expi293F cells grown using Expi293 expression medium. The cells were grown 119 in a cell culture incubator (37°C, ≥80% relative humidity and 8% CO<sub>2</sub>) on an orbital shaker (130 120 rpm). Transfection was done at a final cell density of 3×10<sup>6</sup> viable cells/ml using ExpiFectamine 121 293 transfection kit as per kit's instructions. Culture media were harvested after 5 days post-122 transfection. ST protein was purified using Gravity Flow Strep-Tactin XT resin, whereas RBD 123 protein was purified by HisTrap FF Crude histidine-tagged column on AKTA-Start FPLC system 124 and concentrated using Centricon filter spin columns. Average purified protein yields of 12 mg/l 125 and 61 mg/l were achieved for ST and RBD protein respectively. Spike protein subunits S1 (Native 126 Antigen, REC31806) and S2 (Native Antigen, REC31807) for SARS-CoV-2 were commercially 127 purchased.

128

#### 129 Human IgG and IgA SARS-CoV-2 ELISA

Microtiter plates (Thermo Fisher, 442404) were coated with 50 µl antigen at a concentration of 5
µg/ml in 0.1 M sodium carbonate-bicarbonate buffer (pH 9.6) and incubated overnight at 4°C.
Excess unbound antigen was removed by washing the wells thrice with 200 µl wash buffer (0.1%
Tween 20 in PBS) using an automated plate washer (Tecan HydroFlex). After washing, 100 µl of
blocking buffer (10 mg/ml BSA, 0.05% Tween 20 in PBS) was added to the wells and plates were

135 incubated at room temperature (RT) for 1 h with gentle shaking, followed by washing. Serum 136 samples (50 µl) diluted 1:100 times in PBS with 1 mg/ml BSA were added to the wells. After 30 137 min of incubation at RT, plates were washed 5 times with 300 µl of wash buffer. 50 µl of 138 horseradish peroxidase-conjugated goat anti-Human IgG (GeNei, HPO2) or IgA specific (Sigma-139 Aldrich, A0295) antibody diluted 1:3000 in PBS, 0.1 mg/ml BSA, and 0.05% Tween 20 was added 140 to the wells and incubated at RT for 30 min. Excess antibody-enzyme conjugate was removed by 141 washing the wells 5 times with 300 µl wash buffer. 50 µl of chromogenic tetramethylbenzidine 142 (TMB) substrate was added, and plates were incubated in the dark with constant shaking. The 143 reaction was stopped after 10 min by adding 50 µl of stop solution (8.5 M acetic acid and 0.5 M sulfuric acid). Absorbance was measured at 450 nm using a microplate reader (Thermo Scientific 144 145 Varioskan Flash). Background signal for each sample was estimated by running the same assay 146 without any antigen coating. Corrected OD value was obtained by subtracting the background 147 signal for each sample from its respective OD value in the presence of the antigen. The cut-off 148 value was calculated based on the mean and standard deviation (SD) of the control samples' OD 149 values as mean + 3SD.

150 Antigen concentration for ELISA was determined by titrating the antigens at different 151 concentrations till signal saturation. The ST reactivity to SARS specific antibodies was tested with 152 an ELISA titration of the SARS Spike specific antibody CR3022 (Native Antigen MAB12422, 153 Supplementary Figure 1). Diluted serum was titrated, and IgG ELISA was performed using ST 154 with COVID-19 positive and control samples to determine the optimal sera dilution 155 (Supplementary Figure 2). We selected 1:100 sera dilution for performing all the ELISAs based 156 on the high correlation between area under the sera dilution curves and the signal contrast 157 between COVID-19 and control samples (Supplementary Figure 2c-d).

Head-to-head comparison of ST ELISA and EUROIMMUN Anti-SARS-CoV-2 (IgG) ELISA (S1
protein-based serology kit approved by FDA and ICMR, EI 2606-9601 G [22]) was performed in

160 a double-blind format where the experimenters were blind to the RT-PCR and seropositivity

161 results. EUROIMMUN ELISA was performed as per the manufacturer's instructions.

162 Data analysis

All statistical analyses and visualization were done using custom-written python codes and GraphPad Prism software (v8.4.3). Unpaired two-tailed Student's t-test was used to compare the COVID-19 positive and negative groups. Confidence intervals were calculated using Wilson/Brown's method [23].

167

#### 168 Results

169 Comparison between different spike antigens for human IgG antibodies

170 We compared four different spike protein antigens (S1, S2, RBD and ST) that represent different 171 protein segments commonly being used to evaluate serum reactivity among SARS-CoV-2 172 patients (Figure 1a). 94 COVID-19 samples collected ≥15 days DOS/RT, and 94 control samples 173 were tested for the presence of spike-specific IgG antibodies (Figure 1b). We noted that in-house 174 purified RBD and ST performed better than commercially procured S1 and S2 in terms of 175 sensitivity and intensity of the positive sample signal. ST showed the highest sensitivity (86.2%) 176 followed by RBD (69.9%), while S1 and S2 domains showed very low sensitivity (51.5% and 177 50.0%, respectively) (Table 1). 13 COVID-19 samples were found below the cut-off values for all 178 four antigens.

Among control samples, 64.9% (61/94) were positive for Dengue IgG ELISA, 96.8% (91/94) for Influenza A and 97.8% (92/94) for Influenza B IgG antibodies. This confirmed that these control samples had other detectable virus specific antibodies. Despite this, we obtained specificity >94.7% for all the four antigens (Table 1), suggesting low cross-reactivity of spike antigens s to antibodies for these viruses.

S1, RBD and ST antigens displayed a high correlation among themselves (Pearson's correlation
 coefficient (PCC) >0.75 for all cases). S2 subunit displayed a lower correlation (PCC 0.66-0.68)

to others. This is likely because the structurally buried S2 domain in the spike protein is less
accessible to the antibodies. Nevertheless, the significant correlation across all four antigens
(Figure 1c, PCC >0.65), suggests that antibody responses across all spike antigens are consistent
and that they are all detectable in our ELISA platform.




Figure 1: Reactivity of COVID-19 positive (n=94 samples collected ≥15 days from day of -onset of symptoms or RTPCR positivity) and control sera (n=94) to different antigens (a) Trimeric prefusion spike protein structure (PDB: 5XLR
[24]) shows the antigens used in the ELISA (red: RBD, yellow and red: S1 domain, blue: S2 domain, two monomers
are represented in white) (b) Corrected OD (450 nm) value for S1, S2, RBD and ST protein for each sample is
represented by a point on the scatter plot. Median, 5th percentile and 95th percentile values are shown by horizontal
grey lines. Dotted lines indicate the cut-off values. (mean + 3 x standard deviation of corrected OD values of control

197 samples). (c) Correlation between the four antigens. Corrected OD values for each antigen are plotted against the
198 values for the other antigens. Pearson's correlation coefficient for each pair of antigens is shown on the scatter plots.
199 (d) Receiver operating characteristic curve for each antigen.

ST detected higher OD values, possibly because of the larger number of epitopes available on the full-length soluble trimeric protein. It also displayed the highest contrast between COVID-19 positive and control groups (Figure 1b). Receiver operating characteristic curves indicates that ST is the best candidate for serological testing with the highest area under the curve (Figure 1d). Further, when the ST-based ELISA was repeated in 93 samples (56 COVID-19 positive samples and 37 control samples) in a blind manner, we obtained highly reproducible values (PCC=0.986, Supplementary Figure 3).

Table 1: Sensitivity and specificity with 95% confidence intervals (CI) for different spike antigen-based assays.


| Antigen | Sensitivity (%)  | Specificity (%)  |
|---------|------------------|------------------|
| S1      | 51.1 (41.1-60.9) | 96.8 (91.0-99.1) |
| S2      | 50.0 (40.1-59.9) | 95.7 (89.6-98.3) |
| RBD     | 69.9 (59.9-78.3) | 94.7 (88.1-97.7) |
| ST      | 86.2 (77.8-91.7) | 96.8 (91.0-99.1) |

208

209 Comparison with commercial IgG serology kit

Corrected OD values obtained from ST-based ELISA and ratios obtained from EUROIMMUN test show a good correlation in a double-blind comparison (Figure 2). However, the ST-based ELISA (87.5% (95% CI: 76.4-93.8%)) performed better than the EUROIMMUN IgG kit (67.9% (95% CI: 54.8-78.6%)) in terms of sensitivity (for samples  $\geq$ 15 days DOS/RT). Our results are comparable to values reported by the internal validation report of EUROIMMUN (61.1% for 11-21 days DOS and 81.1% for >11 days post PCR positivity [22]) and lesser than those obtained by others (84.4%

- 216 [25], 89.5% [26]). Specificity values of both methods were comparable 94.6% (95% CI: 82.3-
- 217 99.0%) for ST-based ELISA and 97.3% (95% CI: 86.2-99.9%) for EUROIMMUN kit.



218

Figure 2: Head-to-head double-blinded comparison of EUROIMMUN Anti-SARS-CoV-2 ELISA (IgG) kit and ST ELISA.
 COVID-19 positive samples (filled circles) and control samples (empty circles) are plotted and Pearson's correlation
 coefficient (PCC) between the two test values is indicated for the COVID-19 positive samples.

#### 222 Dynamics of IgG and IgA response in SARS-CoV-2 infections

223 We performed ELISA assays for spike specific IgG and IgA antibodies in sera collected at different 224 time points (≤6, 7-14, 15-21 and ≥22 days POS) using ST protein. Median OD values of IgG and 225 IgA response increased with time (Figure 3a-b; IgG: 0.21, 0.69, 1.40, 1.57, IgA: 0.26, 0.49, 0.77, 226 1.06 for the respective time intervals). Also, the proportion of patients who demonstrated 227 seroconversion increased with time (Figure 3c; IgG: 48.0%, 64.0%, 84.0%, 84.0%, IgA: 50.0, 228 69.6, 72.7, 85.0% for the respective time intervals). In both cases, about 50% of the patients had 229 seroconverted within 6 days from DOS. These findings are in line with previous reports that have 230 shown median time for seroconversion based on spike specific IgG antibodies to be 14 days POS

#### 231 [9,27,28]. A high correlation (PCC = 0.76, Figure 3d) was observed between ranks of IgG and IgA

values for each sample suggesting a comparable and concomitant response to the infection.




Figure 3: Dynamics of ST protein-specific IgG and IgA response. (a-b) Corrected OD values of COVID-19 positive samples collected at different time points post-onset of symptoms (n=25 for each time interval). Value for each sample is represented by a point on the scatter plot. Median, 5th percentile and 95th percentile values are shown by horizontal gray lines. (c) Percentage seroconversion of patients based on IgG and IgA response to ST protein ELISA as a function of time. Vertical lines show 95% confidence intervals (d) Comparison between ranks of the IgG and IgA corrected OD values.

Some individuals did not show detectable spike-specific antibodies (16% for IgG, 15% for IgA) even after 21 days from DOS. This could be due to asymptomatic/mild infection which has been reported to display low antibody titers [6]. We cannot rule-out false-positive PCR results contributing to some of these cases.

244

233

#### 246 Discussion

The trimeric spike protein from SARS-CoV-2 is critical for cellular entry and is prominently 247 248 displayed on the virus. Our results revealed that ST protein displayed better reactivity to COVID-249 19 positive sera when compared to S1, S2 and RBD spike subunit proteins consistent with the 250 larger number of accessible antibody epitopes on ST. While we did not perform neutralization 251 assays, previous studies have shown that the antibodies against RBD are strongly correlated with 252 neutralization of the virus [18,19,29]. Several other regions of the Spike protein, including a region 253 away from receptor binding site [30], S1 domain [31] and S2 domain [32-34] are targets of 254 neutralizing antibodies. Therefore, a high ELISA signal against the ST protein is suggestive of 255 higher levels of a broader spectrum of virus-neutralizing antibodies.

IgG and IgA antibody dynamics show seroconversion in about half of the patients within 6 days POS (also reported earlier, [9,27,35]). Considering the low sensitivity of many existing rapid antigen tests [36–38], a combination of the rapid antigen detection with antibody tests can be employed to increase the detection efficiency of COVID-19 cases during early infection.

Some COVID-19 RT-PCR positive samples did not show reactivity against any of the four antigens. Several other studies have reported limited seroconversion at the time of sera collection [6,39,40]. Nevertheless, highly sensitive serology assays can be critical in determining the seroprevalence in a community as well as help in assessing the immune response/ immunogenicity of vaccines including the temporal course of antibody responses. Our results show that the human antibody response is consistent among the spike antigens, and the spike trimer maybe the best choice of antigen for COVID-19 serology.

267

#### 268 Author contributions

SJ, RK, PV and RR conceptualized the study; CA, DSB, SJ, RK, PV and RR devised methods,
collected samples and clinical data; SJ, RK, PV, RS, SM, AG, CA, DKS, DSB and RR provided
reagents and analysed samples; SJ, RK, PV, RR and BKD curated and/or analysed data; SJ, RK,

- 272 PV, UCMN and RR drafted the manuscript with inputs from others; RR coordinated and 273 supervised the study. All authors approved the final draft of the manuscript.
- 274

#### 275 **Declaration of competing interests**

- 276 The authors declare that there is no conflict of interest.
- 277

#### 278 Acknowledgements

This research has been conducted with the contribution of NCR Biotech Science Cluster BIOREPOSITORY, DBT India consortium for COVID-19 Research and RGUHS-IISc Dengue biomarker research consortium. We thank Florian Krammer, Jason McLellan, Raghavan Varadarajan, Sameer Malladi for providing useful reagents; Sunaina Banerjee and Rohit Dutta for valuable discussions and Khantesh Agrawal for anonymizing the samples. This work was supported by the Indian Institute of Science and CSR funding by Capgemini India. Funding agencies had no role in the design, execution, or interpretation of the study.

286

#### 287 References

- E. Dong, H. Du, L. Gardner, An interactive web-based dashboard to track COVID-19 in
  real time, The Lancet Infectious Diseases. 20 (2020) 533–534.
  https://doi.org/10.1016/S1473-3099(20)30120-1.
- 291 [2] N. Sethuraman, S.S. Jeremiah, A. Ryo, Interpreting Diagnostic Tests for SARS-CoV-2,
  292 JAMA. 323 (2020) 2249–2251. https://doi.org/10.1001/jama.2020.8259.
- J.P. Mathuria, R. Yadav, Rajkumar, Laboratory diagnosis of SARS-CoV-2 A review of
  current methods, Journal of Infection and Public Health. 13 (2020) 901–905.
  https://doi.org/10.1016/j.jiph.2020.06.005.

- Y. Galipeau, M. Greig, G. Liu, M. Driedger, M.-A. Langlois, Humoral Responses and
  Serological Assays in SARS-CoV-2 Infections, Frontiers in Immunology. 11 (2020) 3382.
  https://doi.org/10.3389/fimmu.2020.610688.
- 299 [5] G.P. Milani, L. Dioni, C. Favero, L. Cantone, C. Macchi, S. Delbue, M. Bonzini, E. 300 Montomoli, V. Bollati, B. Albetti, C. Bandi, T. Bellini, M. Buscaglia, C. Cantarella, M. 301 Carugno, S. Casartelli, S. D'Alessandro, F. de Chiara, I. Eberini, L. Ferrari, M. Ferraroni, 302 L. Galastri, C. Galli, M. Hoxha, S. Iodice, C. la Vecchia, A. Manenti, I. Manini, S. Marchi, J. Mariani, E. Pariani, A.C. Pesatori, F. Rota, M. Ruscica, T. Schioppo, L. Tarantini, C.M. 303 304 Trombetta, M. Vicenzi, G. Zanchetta, Serological follow-up of SARS-CoV-2 asymptomatic 305 subjects, Scientific Reports. 10 (2020) 20048. https://doi.org/10.1038/s41598-020-77125-306 8.
- 307 [6] Q.X. Long, X.J. Tang, Q.L. Shi, Q. Li, H.J. Deng, J. Yuan, J.L. Hu, W. Xu, Y. Zhang, F.J.
  308 Lv, K. Su, F. Zhang, J. Gong, B. Wu, X.M. Liu, J.J. Li, J.F. Qiu, J. Chen, A.L. Huang, Clinical
  309 and immunological assessment of asymptomatic SARS-CoV-2 infections, Nature
  310 Medicine. 26 (2020) 1200–1204. https://doi.org/10.1038/s41591-020-0965-6.
- 311 K. Oved, L. Olmer, Y. Shemer-Avni, T. Wolf, L. Supino-Rosin, G. Prajgrod, Y. Shenhar, I. [7] Payorsky, Y. Cohen, Y. Kohn, V. Indenbaum, R. Lazar, V. Geylis, M.T. Oikawa, E. Shinar, 312 313 E. Stovanov, L. Keinan-Boker, R. Bassal, S. Reicher, R. Yishai, A. Bar-Chaim, R. Doolman, 314 Y. Reiter, E. Mendelson, Z. Livneh, L.S. Freedman, Y. Lustig, Multi-center nationwide 315 comparison of seven serology assays reveals a SARS-CoV-2 non-responding 316 seronegative subpopulation, EClinicalMedicine. 29-30 (2020)100651. 317 https://doi.org/10.1016/j.eclinm.2020.100651.
- L. Guo, L. Ren, S. Yang, M. Xiao, D. Chang, F. Yang, C.S. dela Cruz, Y. Wang, C. Wu,
  Y. Xiao, L. Zhang, L. Han, S. Dang, Y. Xu, Q.W. Yang, S.Y. Xu, H.D. Zhu, Y.C. Xu, Q. Jin,
  L. Sharma, L. Wang, J. Wang, Profiling early humoral response to diagnose novel

321 coronavirus disease (COVID-19), Clinical Infectious Diseases. 71 (2020) 778–785.
322 https://doi.org/10.1093/cid/ciaa310.

- 323 [9] J. Zhao, Q. Yuan, H. Wang, W. Liu, X. Liao, Y. Su, X. Wang, J. Yuan, T. Li, J. Li, S. Qian,
- 324 C. Hong, F. Wang, Y. Liu, Z. Wang, Q. He, Z. Li, B. He, T. Zhang, Y. Fu, S. Ge, L. Liu, J.
- Zhang, N. Xia, Z. Zhang, Antibody Responses to SARS-CoV-2 in Patients with Novel
  Coronavirus Disease 2019, Clinical Infectious Diseases. 71 (2020) 2027–2034.
  https://doi.org/10.1093/cid/ciaa344.
- J.M. Dan, J. Mateus, Y. Kato, K.M. Hastie, E.D. Yu, C.E. Faliti, A. Grifoni, S.I. Ramirez,
  S. Haupt, A. Frazier, C. Nakao, V. Rayaprolu, S.A. Rawlings, B. Peters, F. Krammer, V.
  Simon, E.O. Saphire, D.M. Smith, D. Weiskopf, A. Sette, S. Crotty, Immunological memory
  to SARS-CoV-2 assessed for up to 8 months after infection, Science. (2021) eabf4063.
  https://doi.org/10.1126/science.abf4063.
- 333 [11] L. Premkumar, B. Segovia-Chumbez, R. Jadi, D.R. Martinez, R. Raut, A.J. Markmann, 334 C. Cornaby, L. Bartelt, S. Weiss, Y. Park, C.E. Edwards, E. Weimer, E.M. Scherer, N. 335 Rouphael, S. Edupuganti, D. Weiskopf, L. v. Tse, Y.J. Hou, D. Margolis, A. Sette, M.H. 336 Collins, J. Schmitz, R.S. Baric, A.M. de Silva, The receptor-binding domain of the viral spike 337 protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 338 Science Immunology. 5 (2020)patients. eabc8413. 339 https://doi.org/10.1126/SCIIMMUNOL.ABC8413.
- S. Jiang, C. Hillyer, L. Du, Neutralizing Antibodies against SARS-CoV-2 and Other
   Human Coronaviruses, Trends in Immunology. 41 (2020) 355–359.
   https://doi.org/10.1016/j.it.2020.03.007.
- Y. Yamaoka, S.S. Jeremiah, K. Miyakawa, R. Saji, M. Nishii, I. Takeuchi, A. Ryo, Whole
  Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 May Cause
  False-Positive Results in Serological Assays, Clinical Infectious Diseases. (2020).
  https://doi.org/10.1093/cid/ciaa637.

A.P. Katz, F.J. Civantos, Z. Sargi, J.M. Leibowitz, E.A. Nicolli, D. Weed, A.E. Moskovitz,
A.M. Civantos, D.M. Andrews, O. Martinez, G.R. Thomas, False-positive reverse
transcriptase polymerase chain reaction screening for SARS-CoV-2 in the setting of urgent
head and neck surgery and otolaryngologic emergencies during the pandemic: Clinical
implications, Head and Neck. 42 (2020) 1621–1628. https://doi.org/10.1002/hed.26317.

- J. Shang, G. Ye, K. Shi, Y. Wan, C. Luo, H. Aihara, Q. Geng, A. Auerbach, F. Li, Structural
  basis of receptor recognition by SARS-CoV-2, Nature. 581 (2020) 221–224.
  https://doi.org/10.1038/s41586-020-2179-y.
- Y. Huang, C. Yang, X. feng Xu, W. Xu, S. wen Liu, Structural and functional properties of
  SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19, Acta
  Pharmacologica Sinica. 41 (2020) 1141–1149. https://doi.org/10.1038/s41401-020-04854.
- J. Shang, Y. Wan, C. Luo, G. Ye, Q. Geng, A. Auerbach, F. Li, Cell entry mechanisms of
   SARS-CoV-2, Proceedings of the National Academy of Sciences of the United States of
   America. 117 (2020) 11727 LP 11734. https://doi.org/10.1073/pnas.2003138117.
- 362 M.S. Suthar, M.G. Zimmerman, R.C. Kauffman, G. Mantus, S.L. Linderman, W.H. [18] 363 Hudson, A. Vanderheiden, L. Nyhoff, C.W. Davis, O. Adekunle, M. Affer, M. Sherman, S. 364 Reynolds, H.P. Verkerke, D.N. Alter, J. Guarner, J. Bryksin, M.C. Horwath, C.M. Arthur, N. 365 Saakadze, G.H. Smith, S. Edupuganti, E.M. Scherer, K. Hellmeister, A. Cheng, J.A. Morales, A.S. Neish, S.R. Stowell, F. Frank, E. Ortlund, E.J. Anderson, V.D. Menachery, 366 N. Rouphael, A.K. Mehta, D.S. Stephens, R. Ahmed, J.D. Roback, J. Wrammert, Rapid 367 Generation of Neutralizing Antibody Responses in COVID-19 Patients, Cell Reports 368 369 Medicine. 1 (2020) 100040. https://doi.org/10.1016/j.xcrm.2020.100040.
- A. Wajnberg, F. Amanat, A. Firpo, D.R. Altman, M.J. Bailey, M. Mansour, M. McMahon,
  P. Meade, D.R. Mendu, K. Muellers, D. Stadlbauer, K. Stone, S. Strohmeier, V. Simon, J.
  Aberg, D.L. Reich, F. Krammer, C. Cordon-Cardo, Robust neutralizing antibodies to SARS-

- 373 CoV-2 infection persist for months, Science. 370 (2020) 1227–1230.
   374 https://doi.org/10.1126/science.abd7728.
- A.C. Walls, Y.J. Park, M.A. Tortorici, A. Wall, A.T. McGuire, D. Veesler, Structure,
  Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein, Cell. 181 (2020) 281292.e6. https://doi.org/10.1016/j.cell.2020.02.058.
- 378 [21] C.L. Hsieh, J.A. Goldsmith, J.M. Schaub, A.M. DiVenere, H.C. Kuo, K. Javanmardi, K.C.
- Le, D. Wrapp, A.G. Lee, Y. Liu, C.W. Chou, P.O. Byrne, C.K. Hjorth, N. v. Johnson, J.
- 380 Ludes-Meyers, A.W. Nguyen, J. Park, N. Wang, D. Amengor, J.J. Lavinder, G.C. Ippolito,
- 381J.A. Maynard, I.J. Finkelstein, J.S. McLellan, Structure-based design of prefusion-382stabilizedSARS-CoV-2spikes,Science.369(2020)1501–1505.
- 383 https://doi.org/10.1126/SCIENCE.ABD0826.
- 384 [22] EUROIMMUN, Anti-SARS-CoV-2 ELISA (IgG) Instruction for use, 2020.
  385 https://www.fda.gov/media/137609/download.
- L.D. Brown, T.T. Cai, A. das Gupta, Interval estimation for a binomial proportion,
  Statistical Science. 16 (2001) 101–117. https://doi.org/10.1214/ss/1009213286.
- 388 [24] M. Gui, W. Song, H. Zhou, J. Xu, S. Chen, Y. Xiang, X. Wang, Cryo-electron microscopy 389 structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state 390 Cell Research. 27 (2017)for receptor binding. 119–129. 391 https://doi.org/10.1038/cr.2016.152.
- 392 [25] I. Montesinos, D. Gruson, B. Kabamba, H. Dahma, S. van den Wijngaert, S. Reza, V. 393 Carbone, O. Vandenberg, B. Gulbis, F. Wolff, H. Rodriguez-Villalobos, Evaluation of two 394 automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-395 2 antibodies, Journal of Clinical Virology. 128 (2020)104413. 396 https://doi.org/10.1016/j.jcv.2020.104413.
- J. van Elslande, E. Houben, M. Depypere, A. Brackenier, S. Desmet, E. André, M. van
   Ranst, K. Lagrou, P. Vermeersch, Diagnostic performance of seven rapid IgG/IgM antibody

tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients, Clinical Microbiology and
Infection. 26 (2020) 1082–1087. https://doi.org/10.1016/j.cmi.2020.05.023.

- 401 R. Wölfel, V.M. Corman, W. Guggemos, M. Seilmaier, S. Zange, M.A. Müller, D. [27] 402 Niemeyer, T.C. Jones, P. Vollmar, C. Rothe, M. Hoelscher, T. Bleicker, S. Brünink, J. 403 Schneider, R. Ehmann, K. Zwirglmaier, C. Drosten, C. Wendtner, Virological assessment 404 hospitalized patients with COVID-2019, Nature. 581 (2020)465–469. of 405 https://doi.org/10.1038/s41586-020-2196-x.
- 406 [28] K.K.W. To, O.T.Y. Tsang, W.S. Leung, A.R. Tam, T.C. Wu, D.C. Lung, C.C.Y. Yip, J.P.
- 407 Cai, J.M.C. Chan, T.S.H. Chik, D.P.L. Lau, C.Y.C. Choi, L.L. Chen, W.M. Chan, K.H. Chan,
- 408 J.D. Ip, A.C.K. Ng, R.W.S. Poon, C.T. Luo, V.C.C. Cheng, J.F.W. Chan, I.F.N. Hung, Z.
- Chen, H. Chen, K.Y. Yuen, Temporal profiles of viral load in posterior oropharyngeal saliva 409 410 samples and serum antibody responses during infection by SARS-CoV-2: an observational 411 cohort studv. The Lancet Infectious Diseases. 20 (2020)565-574. 412 https://doi.org/10.1016/S1473-3099(20)30196-1.
- 413 [29] F. Amanat, D. Stadlbauer, S. Strohmeier, T.H.O. Nguyen, V. Chromikova, M. McMahon,

K. Jiang, G.A. Arunkumar, D. Jurczyszak, J. Polanco, M. Bermudez-Gonzalez, G. Kleiner,

- T. Aydillo, L. Miorin, D.S. Fierer, L.A. Lugo, E.M. Kojic, J. Stoever, S.T.H. Liu, C.
  Cunningham-Rundles, P.L. Felgner, T. Moran, A. García-Sastre, D. Caplivski, A.C. Cheng,
  K. Kedzierska, O. Vapalahti, J.M. Hepojoki, V. Simon, F. Krammer, A serological assay to
  detect SARS-CoV-2 seroconversion in humans, Nature Medicine. 26 (2020) 1033–1036.
  https://doi.org/10.1038/s41591-020-0913-5.
- M. Yuan, N.C. Wu, X. Zhu, C.C.D. Lee, R.T.Y. So, H. Lv, C.K.P. Mok, I.A. Wilson, A highly
  conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV,
  Science. 368 (2020) 630–633. https://doi.org/10.1126/science.abb7269.
- 423 [31] M. Hoffmann, H. Kleine-Weber, S. Schroeder, N. Krüger, T. Herrler, S. Erichsen, T.S.
  424 Schiergens, G. Herrler, N.H. Wu, A. Nitsche, M.A. Müller, C. Drosten, S. Pöhlmann, SARS-

425 CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell. 181 (2020) 271-280.e8. https://doi.org/10.1016/j.cell.2020.02.052. 426 427 S. Xia, Y. Zhu, M. Liu, Q. Lan, W. Xu, Y. Wu, T. Ying, S. Liu, Z. Shi, S. Jiang, L. Lu, [32] 428 Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike 429 protein. Cellular and Molecular Immunology. 17 (2020)765–767. 430 https://doi.org/10.1038/s41423-020-0374-2.

- J. Duan, X. Yan, X. Guo, W. Cao, W. Han, C. Qi, J. Feng, D. Yang, G. Gao, G. Jin, A
  human SARS-CoV neutralizing antibody against epitope on S2 protein, Biochemical and
  Biophysical Research Communications. 333 (2005) 186–193.
  https://doi.org/10.1016/j.bbrc.2005.05.089.
- 435 H.A. Elshabrawy, M.M. Coughlin, S.C. Baker, B.S. Prabhakar, Human Monoclonal [34] 436 Antibodies against Highly Conserved HR1 and HR2 Domains of the SARS-CoV Spike 437 Protein Are More Broadly Neutralizing. PLoS ONE. (2012)e50366. 7 438 https://doi.org/10.1371/journal.pone.0050366.
- W. Liu, L. Liu, G. Kou, Y. Zheng, Y. Ding, W. Ni, Q. Wang, L. Tan, W. Wu, S. Tang, Z.
  Xiong, S. Zheng, Evaluation of nucleocapsid and spike protein-based enzyme-linked
  immunosorbent assays for detecting antibodies against SARS-CoV-2, Journal of Clinical
  Microbiology. 58 (2020) e00461-20. https://doi.org/10.1128/JCM.00461-20.
- 443 [36] A. Scohy, A. Anantharajah, M. Bodéus, B. Kabamba-Mukadi, A. Verroken, H. Rodriguez-444 Villalobos, Low performance of rapid antigen detection test as frontline testing for COVID-445 19 diagnosis, Journal of Clinical Virology. 129 (2020)104455. https://doi.org/10.1016/j.jcv.2020.104455. 446
- H. Gremmels, B.M.F. Winkel, R. Schuurman, A. Rosingh, N.A.M. Rigter, O. Rodriguez,
  J. Ubijaan, A.M.J. Wensing, M.J.M. Bonten, L.M. Hofstra, Real-life validation of the
  Panbio<sup>™</sup> COVID-19 antigen rapid test (Abbott) in community-dwelling subjects with

450 symptoms of potential SARS-CoV-2 infection, EClinicalMedicine. (2020)
 451 2020.10.16.20214189. https://doi.org/10.1016/j.eclinm.2020.100677.

- 452 [38] ICMR, Advisory on Use of Rapid Antigen Detection Test for COVID-19, 2020.
  453 https://www.icmr.gov.in/pdf/covid/strategy/Advisory for rapid antigen test14062020.pdf.
- 454 [39] E. Brochot, B. Demey, A. Touzé, S. Belouzard, J. Dubuisson, J.L. Schmit, G. Duverlie,
  455 C. Francois, S. Castelain, F. Helle, Anti-spike, Anti-nucleocapsid and Neutralizing
  456 Antibodies in SARS-CoV-2 Inpatients and Asymptomatic Individuals, Frontiers in
  457 Microbiology. 11 (2020) 2468. https://doi.org/10.3389/fmicb.2020.584251.
- 458 [40] H.M. Staines, D.E. Kirwan, D.J. Clark, E.R. Adams, Y. Augustin, R.L. Byrne, M. Cocozza,
- 459 A.I. Cubas-Atienzar, L.E. Cuevas, M. Cusinato, B.M.O. Davies, M. Davis, P. Davis, A.
- 460 Duvoix, N.M. Eckersley, D. Forton, A.J. Fraser, G. Garrod, L. Hadcocks, Q. Hu, M.
- 461 Johnson, G.A. Kay, K. Klekotko, Z. Lewis, D.C. Macallan, J. Mensah-Kane, S. Menzies, I.
- 462 Monahan, C.M. Moore, G. Nebe-Von-Caron, S.I. Owen, C. Sainter, A.A. Sall, J. Schouten,
- 463 C. Williams, J. Wilkins, K. Woolston, J.R.A. Fitchett, S. Krishna, T. Planche, Dynamics of
- 464 IgG seroconversion and pathophysiology of COVID-19 infections, MedRxiv. (2020)
- 465 2020.06.07.20124636. https://doi.org/10.1101/2020.06.07.20124636.